PETALUMA, Calif., Oct. 14, 2020 /PRNewswire/ — Tangram Insurance Services, Inc. (“Tangram”), a Managing General Agency, and Markel Corporation on behalf of its affiliated insurance companies  (“Markel”) today announces the launch of a program to provide excess liability above Tangram’s current program in propane and fuel distribution niche.

Tangram’s program provides comprehensive insurance solutions for dealers and distributors of fuel oil, propane, diesel and gasoline. The additional excess liability capacity that Markel provides will make Tangram a one stop shop for this niche. With the additional capacity, Tangram’s program now has the ability to provide General Liability, Property, Commercial Auto, Workers’ Compensation, Environmental Liability and Excess Liability cover up to $15 million.

“Our downstream energy program is our fastest growing niche.  Tangram’s focus for the past 5 years has been to provide our specialty brokers with meaningful coverage and services from a single source.  With the addition of Markel’s capacity, commitment and experience in the energy space, our brokers and customers have an even more compelling reason to partner with us for the long term,” said Rekha Skantharaja, Tangram’s President & CEO.

Tracy Bernard, Tangram’s Head of Program Development noted, “We are excited to partner with an industry powerhouse like Markel to provide excess liability to this niche. By providing this additional capacity we continue to demonstrate our commitment to the Fuel Distribution industry, providing a full suite of coverages for our broker partners and insureds operating in these challenging times.”

“Tangram provides an excellent underwriting platform for risk analysis, and they have a long history in this insurance space. We’re looking forward to building a solid partnership with Tangram in this line of business and sharing in mutual success and profitability,” said Tim Pasik, Managing Director, US Excess Casualty at Markel.

About Tangram Insurance Services,

Most banks have steered clear of the Federal Reserve’s loan program designed to buoy midsize businesses. One Florida lender is diving in.

Miami-based City National Bank of Florida has embraced the Fed’s Main Street Lending Program, which made its first loan this summer. Of the 252 loans issued through the program in its first three months, City National made nearly 100 of them, extending loans of up to $50 million to companies in states as far away as California and Wyoming.

But otherwise the program, which lets banks make loans to businesses and then sell most of the loan to the Fed, has received a lukewarm reception at best. Fewer than 100 banks have used it, as of the end of September, issuing about $2 billion of loans in a $600 billion program. More than $500 million of that was through City National. None of the nation’s largest banks have made one of the loans.

City National, a subsidiary of Chilean bank Banco de Crédito e Inversiones, said it is confident in its lending. “We’re in the risk management business,” City National Chief Executive Jorge Gonzalez said in an interview. The program’s terms, he said, seem more than reasonable, and the bank has made the loans largely to existing customers.

Using the Main Street program leaves a bank with less additional debt on its books and free to make more loans to other borrowers. Banks also earn fees from borrowers for making the loans.

City National made an early decision to sign up for the program, translating the Fed’s lengthy details into easy guides for customers. Loan officers at the 30-branch bank talked to Fed staffers frequently over the summer.

Miami-based City National Bank of Florida issued

British Academy of Film and Television Arts has announced the 2020 participants of its Newcomers Program. The program expanded to New York for the first time in its history and accepted a record number of first-year female participants.

The initiative to support emerging industry professionals boasts international talent from 20 countries – the U.K., Australia, China, France, Hungary, India, Israel, Italy, Kenya, Mexico, New Zealand, Nigeria, Peru, Philippines, Poland, Russia, Singapore, South Africa, Spain and Turkey.

With 41 new members joining the four-year program, there will be 98 participants, including actors, directors, producers, screenwriters, composers, cinematographers, executives, art directors, production designers, animators, editors and publicists.

“For over 10 years, the BAFTA Newcomers Program has supported hundreds of industry talents making the move to Los Angeles, connecting them to a network of peers and with a program of career support,” said BAFTA Los Angeles chair Kathryn Busby and New York chair Maria Ishak. “We are delighted that this year’s expansion of the program to New York also reflects our strongest year yet for female representation, comprising 78% of our new participants. As our industry continues to adapt to the extraordinary impact of the pandemic, it is as vital as ever to support those who have recently transitioned their careers to the U.S. by welcoming them into BAFTA’s community.”

Every participant will receive access to BAFTA membership programs and new talent events for career development and transition to living and working in the U.S. The program also includes networking opportunities, peer matching and educational programming including the BAFTA briefing sessions and insights series.

More from Variety

Best of Variety

Sign up for Variety’s Newsletter. For the latest news, follow us on Facebook, Twitter, and Instagram.

Source Article

Proposition 118 would create a statewide paid family and medical leave program for workers who’ve earned at least $2,500. The program would allow workers to take up to 12 weeks of leave in most cases, and 16 weeks in the event of pregnancy or childbirth complications. Payments would come from a state-run insurance fund. In workplaces with 10 people or more, workers and employers would each contribute to the fund — at a rate of 0.9% of an employee’s wages — but employers in workplaces of nine or fewer people would be exempt from having to contribute to the premium. Companies with their own programs that meet criteria could opt out.

The case for: Paid family and medical leave would allow workers to stay at home longer with their newborns, care for loved ones in need, or simply prioritize their own health. Without paid leave, workers are often under pressure to return to work more quickly or not to take time off at all. Research has shown that paid leave programs expand employment opportunities and contribute positively to the state economy.

The case against: Workers would be forced to pay into a program that they may never need. That may be especially problematic in a recession, as many individuals and families are having a harder time covering their expenses. Many businesses are struggling, too, and Proposition 118 would add another cost during an uncertain time. Depending on how much the program generates, premium rates may be raised from 0.9% to 1.2%. And while the ballot measure allows certain businesses to opt out, doing so may be complicated and expensive.

Ballot question: “Shall there be a change to the Colorado Revised Statutes concerning the creation of a paid family and medical leave program in Colorado, and, in connection

Re-Affirms Plan to File IND Application by the End of 1Q21, Begin Phase 1 Study in Early 2Q21

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced receipt of feedback to its Type B Pre-IND Meeting Request from the U.S. Food and Drug Administration (“FDA”) that it is in broad agreement with the Company’s planned approach to clinical development of its SARS-CoV-2 vaccine, Terra CoV-2. As a result, the Company believes its timelines for both filing an Investigational New Drug (“IND”) application and the commencement of the Phase 1 study will proceed on schedule. Oragenics expects to file the IND by the end of the first quarter of 2021 and commence patient enrollment in the Phase 1 clinical study early in the second quarter of 2021.

“We are very pleased with the FDA’s response to our Type B Pre-IND meeting request as it permits us to maintain an aggressive development timeline for our Terra CoV-2 vaccine,” said Alan Joslyn, Ph.D., President and Chief Executive Officer of Oragenics. “Important points that are supportive of our planned approach received favorable feedback.”

Dr. Joslyn added, “The FDA’s response is an important step as we work to provide a vaccine against SARS-CoV-2 that is focused on the stabilized prefusion spike protein, with a potential profile that may include lifetime immunity to COVID-19, and storage and distribution at refrigerated temperatures. We believe the commercial opportunity for Terra CoV-2 is robust, and that our vaccine will find its place in the global fight against this deadly virus.”

The FDA has requested additional preclinical animal data for inclusion in the IND filing and plans to provide final comments upon reviewing that data and the Phase 1 trial protocol. Oragenics believes that generating the additional data will not impede the overall development timeline.

About Terra CoV-2